Cisbio Bioassays has announced the launch of its chromogranin A Elisa diagnostic tool, Chromoa.
Chromoa is a sensitive, monoclonal antibody-based assay used to identify increased protein levels in serum when a neuroendocrine tumour is present in the human body.
The most common neuroendocrine tumours affect the adrenal gland, the pancreas and the digestive track.
Chromogranin A (CgA) is an increasingly essential analyte for the detection and monitoring of these tumours, as well as prostate cancer, which can evolve into an aggressive, neuroendocrine form.
Based on the same monoclonal antibody as CgA-Riact, Chromoa offers the same results but in an Elisa format.
Cisbio said that this kit features a long shelf life and offers easier stock management for technicians.
It is particularly suitable for laboratories that do not use radioactive kits.
Enzyme-linked immunosorbent assays (Elisa) have been used for the quantitative analysis of protein blood samples for two decades and can be adopted by any laboratory.
